- Home
- APRE
as 07-26-2024 4:00pm EST
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its product candidate, APR-246, is a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML).
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DOYLESTOWN |
| Market Cap: | 21.7M | IPO Year: | 2019 |
| Target Price: | $15.50 | AVG Volume (30 days): | 5.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.91 - $8.85 | Next Earning Date: | 08-08-2024 |
| Revenue: | $963,800 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 4.93% | Revenue Growth (next year): | -33.33% |
Stock Insider Trading Activity of Aprea Therapeutics Inc. Common stock (APRE)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hamill John P. | APRE | SrVP/CFO/Prin Fin & Acct Ofcr | Mar 13 '24 | Buy | $7.29 | 1,010 | $7,362.90 | 15,503 | SEC Form 4 |
| Seizinger Bernd R. | APRE | Director | Mar 13 '24 | Buy | $7.29 | 6,860 | $50,009.40 | 33,685 | SEC Form 4 |
| HENNEMAN JOHN B III | APRE | Director | Mar 13 '24 | Buy | $7.29 | 6,860 | $50,009.40 | 8,139 | SEC Form 4 |
| Gilad Oren | APRE | President, CEO | Mar 13 '24 | Buy | $7.29 | 2,000 | $14,580.00 | 324,770 | SEC Form 4 |
Latest Aprea Therapeutics Inc. Common stock News
APRE Breaking Stock News: Dive into APRE Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
Will Aprea Therapeutics (NASDAQ:APRE) Spend Its Cash Wisely?
GlobeNewswire
a month ago
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
GlobeNewswire
a month ago
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
Simply Wall St.
a month ago
Pleasing Signs As A Number Of Insiders Buy Aprea Therapeutics Stock
GlobeNewswire
2 months ago
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
GlobeNewswire
2 months ago
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
GlobeNewswire
2 months ago
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
GlobeNewswire
3 months ago
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Compare APRE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APRE Aprea Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.